Himalaya Nutravedics India Limited · BSE:HNIL

Himalaya Nutravedics India — H1 FY2027 Earnings Presentation

26 slides from Himalaya Nutravedics India's earnings presentation, Nov 13, 2026

  1. Slide 1: Regulation 30 Disclosure Letter - Investor Presentation

    HIMALAYA NUTRAVEDICS INDIA LIMITED (formerly known as HIMALAYA NUTRAVEDICS INDIA PRIVATE LIMITED) CIN: L24110TG2022PLC163732 REGISTERED OFFICE: Plot No. 101/A, Phase-II1, Industrial Development Park, Cherlapally, Hindustan Cables Ltd, Hyderabad, Uppal, Telangana, India- 500051. EMAIL ID: himalayanut

  2. Slide 2: Investor Presentation - H1 FY27

    HIMALAYA NUTRAVEDICS J.—- INDIALIMITED i Investor Presentation - H1 FY2/

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement This presentation is for information purposes only and does not constitute an offer or invitation to sell or the solicitation of an offer or invitation to purchase any securities ("Securities") of Himalaya Nutravedics India limited (or the "company") in India or any other juris

  4. Slide 4: Agenda

    | Agenda O Executive Summary 02 About Himalaya Nutravedics India Ltd. S Comprehensive Product Portfolio 04 Industry Landscape B Competitive MOATS 06 Investment Rationale o7 Financial Performance

  5. Slide 5: Executive Summary - H1 FY27

    | Executive Summary - HIFY27 >%>> @ =/ Revenue from Operations Cashflow from Operations Cash Conversion Cycle % 2,739.8 lakhs YoY +35.8% (vs3:-384.2 © % -65.5 lakhs 230 (vs 201in FY25) O lakhs in FY25) O EBITDA EBITDA Margin Inventory Turnover Ratio (= ooo X 567.2 lakhs YoY +51.1% 20.7% +210 bps 2.4

  6. Slide 6: About the Company

    | About the Company Himalaya Nutravedics India Limited is an integrated ayurvedic and nutraceutical company engaged in the manufacturing, marketing and distribution of a diversified portfolio of classical Particulars (In ¥ Lakhs) H1FY27 FY26 FY25 (Shastric) ayurvedic formulations, proprietary ayurve

  7. Slide 7: Our Journey

    | Our Journey * Incorporated as Himalaya Nutravedics + Further expanded market presence to Uttar » Operations commenced in Bihar and India Private Limited. Pradesh, Jharkhand and Delhi. Odisha in July 2026. * Commenced commercial manufacturing * Successful listing of the company on the operations fr

  8. Slide 8: Business Model

    | Business Model Our Brand Business Own-Brand Portfolio Classification = Classical Ayurvedic g/~ Prescription-led, doctor engagement driven offline sales model. ' Nature: Traditional medicines Basis of Formulation: mkds Multi-tier distribution via Super-Stockists, Stockists, and Retail Established a

  9. Slide 9: Management Commentary - H1 FY27

    | Management Commentary - H1 FY27 “H1 FY27 has been an encouraging period for Himalaya Nutravedics India Limited, marked by sustained business growth and improved operating profitability. Revenue from operations grew 35.8% year-on-year to X2,739.8 Lakhs, while EBITDA increased 51.1% to X567.2 Lakhs,

  10. Slide 10: Leadership Team

    | Leadership Team ROHIT ASAWA DIVYA ASAWA Chairman & Managing Director (Promoter Group) Non-Executive Director (Promoter Group) Rohit Asawa holds a degree in Electronics and Communication Divya Asawa holds a degree in Commerce from Osmania University and Engineering from Jawaharlal Nehru Technologic

  11. Slide 11: Product Portfolio

    | Product Portfolio Product Category Pain Management & Musculoskeletal Care - Medicated oils, gels, and targeted anti-inflammatory oral doses. Digestive & Gut Health - Classical and proprietary formulations for Gastrointestinal support. Softgel Capsules Women’s Wellness & Infertility - Specialized a

  12. Slide 12: Proprietary Portfolio - Ayurvedic

    | Proprietary Portfolio - Ayurvedic & W) Orthopedic & Pain Chronic & Lifestyle Gastrointestinal & Men's Health & Specialty Management Diseases Liver Health Vitality Care Comprehensive care for Targeted management for Formulations for gut health, Specialized care for male Focused treatments across ar

  13. Slide 13: Nutraceutical Product Portfolio

    | Nutraceutical Product Portfolio 1@ 7] \ Cogrite-plus Tablets Lythimin Tablets Lythmin Plus Tablets Cogrite Tablets Key Actives: Coenzyme QI0, Key Actives: Astaxanthin, Key Actives: Omega-3 Fatty Acids Key Actives: Multivitamins, Coenzyme Q10, Elemental Zinc, (DHA & EPA), Essential Multivitamins Mu

  14. Slide 14: Pan-India Reach Through a Diversified Distribution Network

    | Pan-India Reach Through a Diversified Distribution Network = x> Distribution Footprint * Products reach 20 states and 1 Union Territory across India through a multi-tier network of super stockists, stockists, and retailers. + Deep penetration in key markets: Kerala, Gujarat, Uttar Pradesh, and Tel

  15. Slide 15: Historical Performance (1/2)

    | Historical Performance (1/2) e N e ™ e N Revenue from Operations (In X Lakhs) EBITDA (In X Lakhs) Profit After Tax (PAT) (In X Lakhs) 4.306.8 810.3 721.7 2,099.7 1,442.6 299.0 2232 93.5 " FY24 FY25 FY26 H1 FY27 FY24 FY25 FY26 H1 FY27 FY24 FY25 FY26 H1 FY27 4 N\ 4 N\ 4 N\ EPS (n ) EBITDA Margin (n

  16. Slide 16: Historical Performance (2/2)

    | Historical Performance (2/2) { 3\ ( )\ )\ ROE! (In %) ROCE! (In %) Debt-to-Equity (In Times) 55.0% 37.0% 37.3% 9 44.1% 30.2% 17.0% FY24 FY25 FY26 H1 FY27 FY24 FY25 FY26 H1 FY27 FY25 FY26 H1 FY27 ( \ { )\ \ Net Worth (In X Lakhs) Debtor Days (In Days) Current Ratio (In Times) S 89.7 89.0 2.7 2.7 1,

  17. Slide 17: Operational Metrics

    | Operational Metrics Product Segment Mix (%) Capacity Utilization (%) Geographic Footprint Business Segment Mix (%) 5.4% 1.8% S0 - 311% 64% 54.4%) 50.7%) 56% 48.9% 45.3% 72.0% 43% 921% 94.6% 98.2% 34% 79.3% 29% P 68.9% 45.6% 49.5% 47.7% 51.1% 54.7% a0 19.7% nI I FY24 FY25 FY26 H1 FY27 FY24 FY25 FY2

  18. Slide 18: Industry Growth Drivers

    | Industry Growth Drivers » The nutraceutical, ayurvedic, and wellness products industry in India is experiencing a structural shift in consumer behavior towards digital platforms. » Consumers today increasingly rely on digital channels, including search 16.5 . . . . 6 engines, social media platform

  19. Slide 19: Industry Growth Drivers

    | Industry Growth Drivers Industry Tailwinds & Drivers Product Segment Market Forecast 2024-35 (USD billion) * High-Growth Trajectory for Herbal & Vitamin Segments: There is a strong structural demand for natural and plant-based formulations. Status as of 2024 m Projected by 2035 * The herbal produc

  20. Slide 20: Competitive Moats

    | Competitive Moats il Integrated Manufacturing Practitioner-Driven Diversified Therapeutic Rapid Geographic Enduring Ecosystem & Capabilities Prescription Model Coverage Scale Supply Chain « WHO-GMP & ISO Certified Healthcare Professional » Comprehensive Portfolio: * Pan-India Footprint with Robust

  21. Slide 21: Strategic Growth Plan

    | Strategic Growth Plan 4. Deepening Geographic Reach & Export Readiness 3. Expanding Own-Branded The Company aims to deepen its domestic footprint beyond its existing 16 States and 1 Portfolio & High-Margin SKUs Union Territory by strengthening its multi- Building on the growth of its proprietary t

  22. Slide 22: Investment Rationale

    | Investment Rationale Positioned in High-Growth Nutraceutical & Ayurvedic Segments Himalaya Nutravedics operates across two fast-growing wellness segments ayurvedic formulations and nutraceutical supplements—catering to therapeutic areas such as orthopedic care, metabolic disorders, gastroenterolog

  23. Slide 23: Income Statement

    | Income Statement ¥ Lakhs Unless Otherwise Mentioned Particulars H1FY27 H1FY26 YoY change (%) FY26 Revenue from Operations 2,739.8 2,017.9 35.8% 4,306.8 Cost of materials consumed including finished goods and WIP 2,739.8 2,017.9 33.6% 2,689.7 Employee benefits expense 132.3 118.5 1.6% 240.7 Other e

  24. Slide 24: Balance Sheet

    | Balance Sheet X Lakhs Unless Otherwise Mentioned Assets H1FY27 Property plant & equipment 86.5 96.0 120.5 140.9 Capital WIP 0.0 0.0 0.0 0.0 Long term loans & advances - - - - Other non-current assets (incl intangible assets & non-current investments) 175.7 176.2 48.9 10.7 Inventories 1,322.4 891.5

  25. Slide 25: Cash Flow Statement

    | Cash Flow Statement ¥ Lakhs Unless Otherwise Mentioned Particulars H1FY27 FY26 FY25 FY24 Net cash from / (used in) operating activities (65.5) (384.2) (139.1) (55.1) Net cash from / (used in) investing activities A.7) (5.8) (22.6) (109.8) Net cash from / (used in) financing activities 2,584.4 527.

  26. Slide 26: Thank You

    Thank You For any further information/factory visit request, please contact: Company Himalaya Nutravedics India Limited [email protected] Investor Relations Consultant CAPITAL BRIDGE ADVISORS Capital Bridge Advisory Service Private Ltd Rishi Kothari Krisha Anandpara [email protected] kri

Himalaya Nutravedics India — H1 FY2027 Earnings Presentation on 6ix